ESTRO 2024 - Abstract Book

S2531

Clinical - Urology

ESTRO 2024

50.52% experienced acute genitourinary toxicity G1, 5.85% G2, and 0.42% G3. Acute G1 gastrointestinal toxicity was experienced in 8,14%, G2 in 0.84% and G3 in 0.21%. After 6 months, G1 genitourinary toxicity was reported in 3.35%, G2 in 0.72%, G1 gastrointestinal toxicity in 0.24%. There were 5 cases of actinic proctitis and 3 of them required argon laser coagulation.

Conclusion:

SBRT is positioned as a safe treatment for localised prostate low and favourable intermediate risk cancer, with excellent disease control and a low toxicity profile.

Keywords: Prostate cancer, SBRT, Radiotherapy

References:

Tree AC, Ostler P, van der Voet H, Chu W, Loblaw A, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Armstrong J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Duffton A, Brand DH, Henderson D, Morrison K, Brown S, Pugh J, Burnett S, Mahmud M, Hinder V, Naismith O, Hall E, van As N; PACE Trial Investigators. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2022 Oct;23(10):1308-1320. Gómez-Aparicio MA, Valero J, Caballero B, García R, Hernando-Requejo O, Montero Á, Gómez-Iturriaga A, Zilli T, Ost P, López-Campos F, Couñago F. Extreme Hypofractionation with SBRT in Localized Prostate Cancer. Curr Oncol. 2021 Aug 3;28(4):2933-2949

2443

Digital Poster

Clarity based clinical safety margins for Prostate SBRT with intrafraction motion monitoring

Devangana Bora, Vibhay Pareek, Adila Amariyil, Gopikrishna Shyam, Seema Sharma, Subhash Gupta, Haresh Kunhiparambath P

All India Institute of Medical Sciences, Radiation Oncology, New Delhi, India

Purpose/Objective:

Transperineal 4D ultrasound (TPUS) (ClarityTM) has been an excellent measure to monitor intra-fractional prostate motion for prostate stereotactic body radiotherapy (SBRT). In this prospective study, we assessed intrafraction prostate motion in real-time using transperineal 4D ultrasound and analyzed the motions to validate clinical safety margins.